Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR.

J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

2.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

3.

Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Chen HZ, Tsai SY, Leone G.

Nat Rev Cancer. 2009 Nov;9(11):785-97. doi: 10.1038/nrc2696. Review.

4.

Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.

Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S.

Oncogene. 2010 Jan 14;29(2):237-50. doi: 10.1038/onc.2009.322. Epub 2009 Oct 5.

PMID:
19802001
5.

Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.

Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ.

Cancer Res. 2009 Oct 1;69(19):7793-802. doi: 10.1158/0008-5472.CAN-08-3810. Epub 2009 Sep 22.

6.

Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene.

Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, Ginsberg D, Plymate SR, Werner H.

Growth Horm IGF Res. 2010 Feb;20(1):68-72. doi: 10.1016/j.ghir.2009.08.001. Epub 2009 Aug 22.

PMID:
19703789
7.

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Knudsen KE, Scher HI.

Clin Cancer Res. 2009 Aug 1;15(15):4792-8. doi: 10.1158/1078-0432.CCR-08-2660. Epub 2009 Jul 28. Review.

8.

Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M.

Cell. 2009 Jul 23;138(2):245-56. doi: 10.1016/j.cell.2009.04.056.

9.

NF-kappaB regulates androgen receptor expression and prostate cancer growth.

Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI, Gerald WL.

Am J Pathol. 2009 Aug;175(2):489-99. doi: 10.2353/ajpath.2009.080727. Epub 2009 Jul 23.

10.

Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.

Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J, Scher HI.

BJU Int. 2010 Feb;105(4):462-7. doi: 10.1111/j.1464-410X.2009.08747.x. Epub 2009 Jul 14.

11.

Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.

Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP.

Cancer Res. 2009 Jun 15;69(12):5202-9. doi: 10.1158/0008-5472.CAN-09-0026. Epub 2009 Jun 2.

12.

E2F1 Induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells.

Zheng C, Ren Z, Wang H, Zhang W, Kalvakolanu DV, Tian Z, Xiao W.

Cancer Res. 2009 Mar 15;69(6):2324-31. doi: 10.1158/0008-5472.CAN-08-4113. Epub 2009 Mar 10.

13.

Tailoring to RB: tumour suppressor status and therapeutic response.

Knudsen ES, Knudsen KE.

Nat Rev Cancer. 2008 Sep;8(9):714-24. doi: 10.1038/nrc2401. Review.

14.

E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites.

Rabinovich A, Jin VX, Rabinovich R, Xu X, Farnham PJ.

Genome Res. 2008 Nov;18(11):1763-77. doi: 10.1101/gr.080622.108. Epub 2008 Oct 3.

15.

Cellular mechanisms of tumour suppression by the retinoblastoma gene.

Burkhart DL, Sage J.

Nat Rev Cancer. 2008 Sep;8(9):671-82. doi: 10.1038/nrc2399. Review.

PMID:
18650841
16.

Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity.

Link KA, Balasubramaniam S, Sharma A, Comstock CE, Godoy-Tundidor S, Powers N, Cao KH, Haelens A, Claessens F, Revelo MP, Knudsen KE.

Cancer Res. 2008 Jun 15;68(12):4551-8. doi: 10.1158/0008-5472.CAN-07-6392.

17.

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.

Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249.

18.

Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.

Wang LG, Johnson EM, Kinoshita Y, Babb JS, Buckley MT, Liebes LF, Melamed J, Liu XM, Kurek R, Ossowski L, Ferrari AC.

Cancer Res. 2008 Apr 15;68(8):2678-88. doi: 10.1158/0008-5472.CAN-07-6017.

19.

RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis.

Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS, Aronow BJ, Thorgeirsson SS, Knudsen ES.

Gastroenterology. 2007 Sep;133(3):976-84. Epub 2007 Jun 20.

PMID:
17854601
20.

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE.

Cancer Res. 2007 Jul 1;67(13):6192-203.

Supplemental Content

Support Center